TBPH
Theravance Biopharma, Inc.
Key Financials
Net Income
$105.9M
↑ 73.5%
Operating Income
$-3602000
↓ 118.0%
Revenue
$107.5M
↑ 134.2%
Total Assets
$485.6M
↑ 37.1%
EPS (Diluted)
$2.06
↑ 79.1%
Shareholders' Equity
$296.7M
↑ 69.0%
Cash & Equivalents
$167.8M
↑ 344.0%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
| 4 | 5/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TBPH |
| Company Name | Theravance Biopharma, Inc. |
| CIK | 1583107 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | CA |
| Phone | 650-808-6000 |